Original paper

Safety profile of autologous macrophage therapy for liver cirrhosis

Volume: 25, Issue: 10, Pages: 1560 - 1565
Published: Oct 1, 2019
Abstract
Therapies to reduce liver fibrosis and stimulate organ regeneration are urgently needed. We conducted a first-in-human, phase 1 dose-escalation trial of autologous macrophage therapy in nine adults with cirrhosis and a Model for End-Stage Liver Disease (MELD) score of 10–16 (ISRCTN 10368050). Groups of three participants received a single peripheral infusion of 107, 108 or up to 109 cells. Leukapheresis and macrophage infusion were well...
Paper Details
Title
Safety profile of autologous macrophage therapy for liver cirrhosis
Published Date
Oct 1, 2019
Volume
25
Issue
10
Pages
1560 - 1565
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.